Using a variety of techniques, Sangui Bio is focused identifying disease-specific biomarkers. We aim to do this by using proprietary methods to fractionate liquid blood and dried blood samples, thereby producing large protein datasets. This, combined with clinical and lifestyle data presents a rich tapestry of health.
Figure 1. Schematic of how Sangui Bio processes blood to produce a broad range of samples for the purposes of biomarker discovery including RBC fractions and dried blood samples. The image of a flask identifies the samples that are analysed following production.
At home patient-centric longitudinal sampling is ideal for addressing target discovery requirements using a multi-omics approach. The Sangui Bio platform incorporates proprietary methods that enable rapid analysis using cutting edge laboratory techniques and we have obtained excellent results from both fresh and frozen samples. Sample preparation is low cost and is readily scalable for large patient cohorts.
Liquid blood and RBC fractionation
The discovery that RBCs are a major reservoir of cytokines is changing the way clinical researchers look for markers of disease. Sangui Bio quantifies proteins in whole blood, plasma, RBCs, and their membranes. We believe the Sangui Bio suite of RBC analyses is an important aspect of screening for clinical biomarkers.
Our strong clinical network is what has enabled us to do high quality clinical research. Our network encompasses leading investigators, research and clinical trials, with access to diverse patient populations, population-based studies, and at-home blood collection.
The recent shift towards personalised medicine has highlighted how variable patients with the same diagnosis can be. These include lifestyle choices like diet and exercise and genetic predisposition. We are seeking to track these factors longitudinally in our clinical studies to enable improved stratification.